Provider support helps patients navigate those decisions, achieve better outcomes, and, when appropriate, successfully reduce or discontinue medication over time
In NMO the myelin deteriorates mostly in the optic nerve, which can lead to blindness, and in the spinal cord
Here is a summary of the data for Utah : Share of all patients who take a GLP-1: 0.7% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.4% Share of female patients with an obesity diagnosis who take a GLP-1: 5.1% Share of GLP-1 users that are female: 60.4% For reference, here are the statistics for the entire United States: Share of all patients who take a GLP-1: 1.0% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.2% Share of female patients with an obesity diagnosis who take a GLP-1: 5.2% Share of GLP-1 users that are female: 64.7% For more information, a detailed methodology, and complete results, see U.S
People philosophically opposed to pharmaceutical interventions or preferring natural approaches benefit from having legitimate options backed by some research rather than completely unsubstantiated supplements
However, unless -cell failure occurs simultaneously, insulin resistance will not lead to T2DM
